StockData
BioRestorative Therapies, Inc. logo

BioRestorative Therapies, Inc. (BRTX) stock

BRTXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 8/30
$1.42−0.07 (-4.70%)

Close on Nov 16, 2026Market cap $36.18MP/E –Yield –

Earnings

BioRestorative Therapies's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2024
$230.70K
EPS, Q3 FY2024
-$0.13
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of BioRestorative Therapies's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2025ended Sep 30, 2025Nov 12, 2025after the close–––Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025after the close–––Release
Q1 FY2025ended Mar 31, 2025May 14, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025after the close–––Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024after the close$230.70K–-$0.13Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024after the close–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

BioRestorative Therapies has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When BioRestorative Therapies puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases BioRestorative Therapies filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Update
  4. Update
  5. Results
  6. Update
  7. Update
  8. Results
  9. Update
  10. Update
  11. Results
  12. Results
  13. Update
  14. Update
  15. Results

See a number that looks wrong?